An adjusted indirect treatment comparison (ITC) of enzalutamide (ENZ) versus docetaxel (DOC) for metastatic hormone-sensitive prostate cancer (mHSPC)

被引：0
|
作者：
Ohlmann, Carsten [1 ]
Armstrong, Andrew [2 ]
Gratzke, Christian [3 ]
Sugg, Jennifer [4 ]
Ganguli, Arijit [4 ]
Dornstauder, Eugen [5 ]
Gross-Langenhoff, Marco [5 ]
Brauner, Reinhard [5 ]
Stenzl, Arnulf [6 ]
机构：
[1] Johanniter Krankenhaus Bonn, Bonn, Germany
[2] Duke Univ, Durham, NC USA
[3] Univ Klinikum Freiburg, Freiburg, Germany
[4] Astellas, Northbrook, IL USA
[5] Astellas Pharma GmbH, Munich, Germany
[6] Eberhard Karls Univ Tubingen, Tubingen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
881
引用
收藏
页码：109 / 109
页数：1
相关论文
共 50 条
  • [31] Enzalutamide versus abiraterone as a radiosensitizer in hormone-sensitive prostate cancer cells
    Ghashghaei, Maryam
    Muanza, Thierry
    Alaoui-Jamali, Moulay
    Paliouras, Miltiadis
    Niazi, Mohammad Tamim
    CANCER RESEARCH, 2018, 78 (13)
  • [32] Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
    Kenrick Ng
    Shievon Smith
    Jonathan Shamash
    Oncology and Therapy, 2020, 8 : 209 - 230
  • [33] Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
    Ng, Kenrick
    Smith, Shievon
    Shamash, Jonathan
    ONCOLOGY AND THERAPY, 2020, 8 (02) : 209 - 230
  • [34] Erstlinientherapie beim metastasierten hormonsensitiven Prostatakarzinom (mHSPC)First-line treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    H. Rexer
    S. Feyerabend
    M. Graefen
    Forum, 2023, 38 (3) : 238 - 239
  • [35] AUO First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC)
    Rexer, H.
    Feyerabend, S.
    Graefen, M.
    UROLOGIE, 2023, 62 (04): : 441 - 442
  • [36] Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy
    Yanagisawa, Takafumi
    Hata, Kenichi
    Narita, Shintaro
    Hatakeyama, Shingo
    Mori, Keiichiro
    Yata, Yuji
    Sano, Takayuki
    Otsuka, Takashi
    Hara, Shuhei
    Miyajima, Keiichiro
    Enei, Yuki
    Fukuokaya, Wataru
    Nakazono, Minoru
    Matsukawa, Akihiro
    Miki, Jun
    Habuchi, Tomonori
    Ohyama, Chikara
    Shariat, Shahrokh F.
    Kimura, Takahiro
    PROSTATE, 2023, 83 (06): : 563 - 571
  • [37] Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
    Lendorf, Maria Elisabeth
    Petersen, Peter Meidahl
    Svendsen, Andrea Steen
    Lindberg, Henriette
    Brasso, Klaus
    EUROPEAN UROLOGY OPEN SCIENCE, 2021, 24 : 25 - 33
  • [38] Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy
    Yanagiswawa, T.
    Hata, K.
    Narita, S.
    Hatakeyama, S.
    Mori, K.
    Yata, Y.
    Sano, T.
    Otsuka, T.
    Hara, S.
    Miyajima, K.
    Enei, Y.
    Fukuokaya, W.
    Nakazono, M.
    Matsukawa, A.
    Miki, J.
    Habuchi, T.
    Ohyama, C.
    Shariat, S. F.
    Kimura, T.
    EUROPEAN UROLOGY, 2023, 83
  • [39] Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report
    Thomson, Alastair
    Gunn, Lucinda
    Victor, Deborah
    Adamson, Ellis
    Thakrar, Kashyap
    RESEARCH AND REPORTS IN UROLOGY, 2024, 16 : 245 - 252
  • [40] UpFrontPSMA: A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)
    Azad, A. A.
    Bressel, M.
    Tan, H.
    Voskoboynik, M.
    Suder, A.
    Weickhardt, A. J.
    Guminski, A.
    Francis, R. J.
    Saghebi, J.
    Dhiantravan, N.
    Joshua, A.
    Emmett, L.
    Murphy, D.
    Hsiao, E.
    Lee, S. T.
    Pattison, D. A.
    Nadebaum, D.
    Kirkwood, I. D.
    Hofman, M. S.
    ANNALS OF ONCOLOGY, 2024, 35 : 1255 - 1256
12345